KMT2A and acute myeloid leukemia: Similarly, in elderly unfit, previously untreated KMT2A-rearranged or NPM1-mutated AML patients, the BEAT-AML consortium reported data from an ongoing phase-I trial demonstrating an ORR (excluding PR) of 100% and a CR/CRh rate of 77% for the combination of revumenib with AZA/VEN [111].